Welcome to our dedicated page for Ironwood Pharmaceuticals news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals stock.
Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported Q1 2022 results, highlighting an 11% year-over-year growth in LINZESS® (linaclotide) prescription demand. The U.S. net sales of LINZESS reached $232 million, marking an 8% increase year-over-year. Total revenue for the quarter was $98 million, with collaboration revenue from LINZESS at $94 million. The company achieved a GAAP net income of $39 million and ended the quarter with $593 million in cash. Ironwood remains focused on pipeline development and ongoing clinical trials for new GI treatments.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its first quarter 2022 investor update conference call on May 5, 2022, at 8:30 a.m. Eastern Time. Participants can join via phone or access a webcast from Ironwood's website. A replay will be available from 11:30 a.m. ET on the same day until May 19, 2022. Ironwood is known for its development of LINZESS®, a leading treatment for gastrointestinal diseases, aiming to improve care standards for patients with IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD), a leading gastrointestinal healthcare company, announced management presentations at two key investor conferences. The events include the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 a.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET. Live webcasts of these presentations will be available on Ironwood's website, with replays accessible for 14 days after the conferences. Ironwood is dedicated to advancing treatment for GI diseases, notably with its leading product LINZESS®.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported a strong financial performance for 2021, with total revenues reaching $414 million, driven largely by $400 million from U.S. LINZESS collaboration revenue. The company reported a GAAP net income of $528 million, boosted by a non-recurring tax benefit. Ironwood also made strategic advancements in its pipeline, initiating clinical studies for IW-3300 and CNP-104, targeting unmet medical needs in visceral pain and primary biliary cholangitis (PBC). The company ended 2021 with $620 million in cash and equivalents, positioning itself favorably for growth in 2022.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced an investor update conference call for its fourth quarter and full year 2021, scheduled for February 17, 2022, at 8:30 a.m. ET. Participants can dial in at (888) 330-2384 for US/Canada or (240) 789-2701 internationally, using conference ID 4671230. The call will be available for replay after 11:30 a.m. ET on the same day until March 3, 2022. Ironwood is focused on advancing treatments for gastrointestinal diseases, led by its product LINZESS®.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced strong financial guidance, projecting LINZESS to exceed $1 billion in U.S. net sales for 2021, achieving blockbuster status. The company authorized a share repurchase program worth $150 million. For 2022, Ironwood expects low single-digit net sales growth for LINZESS, total revenues of $420-$430 million, and adjusted EBITDA exceeding $250 million. The company will present these insights at the J.P. Morgan Healthcare Conference on January 12, 2022.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced that CEO Tom McCourt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. ET. The presentation will be held virtually, and investors can access the live audio webcast via the company’s website. A replay will be available for 14 days post-conference. Ironwood is focused on advancing treatments for gastrointestinal diseases, including its flagship product LINZESS® for IBS-C and CIC.
Ironwood Pharmaceuticals announced the appointment of Sravan K. Emany as the new Chief Financial Officer effective December 6, 2021. Emany, who has extensive experience in financial strategy within the healthcare sector, will oversee all financial operations and report to CEO Thomas McCourt. McCourt expressed confidence that Emany's expertise will enhance Ironwood's impact on gastrointestinal (GI) healthcare and benefit shareholders. Previously, Emany held leadership roles at Integra LifeSciences and has 18 years in investment banking.
Ironwood Pharmaceuticals reported a strong third quarter in 2021, with GAAP net income of $55.8 million and adjusted EBITDA of $65.5 million. LINZESS prescription demand surged 12% year-over-year, driving U.S. net sales to $253 million, up 5% from the previous year. Ironwood ended the quarter with $574 million in cash. The company expanded its pipeline by entering into an option agreement with COUR Pharmaceuticals for CNP-104, targeting primary biliary cholangitis, a rare autoimmune disease. The firm anticipates 6% to 8% growth in LINZESS net sales for 2021.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced a collaboration with COUR Pharmaceutical for the investigational therapy CNP-104, aimed at treating Primary Biliary Cholangitis (PBC), a rare autoimmune disease affecting 133,000 people in the U.S. Ironwood will pay approximately $20 million upfront and could pay up to $475 million in milestones and royalties. The FDA has accepted the IND application for CNP-104, with clinical trials expected to commence soon, presenting significant potential for market expansion.